Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Share-based Compensation: 2013-2024

Historic Share-based Compensation for Zevra Therapeutics (ZVRA) over the last 12 years, with Dec 2024 value amounting to $14.9 million.

  • Zevra Therapeutics' Share-based Compensation fell 54.85% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year increase of 0.06%. This contributed to the annual value of $14.9 million for FY2024, which is 150.35% up from last year.
  • As of FY2024, Zevra Therapeutics' Share-based Compensation stood at $14.9 million, which was up 150.35% from $6.0 million recorded in FY2023.
  • In the past 5 years, Zevra Therapeutics' Share-based Compensation registered a high of $14.9 million during FY2024, and its lowest value of $2.4 million during FY2021.
  • Over the past 3 years, Zevra Therapeutics' median Share-based Compensation value was $6.0 million (recorded in 2023), while the average stood at $8.4 million.
  • In the last 5 years, Zevra Therapeutics' Share-based Compensation tumbled by 43.51% in 2020 and then skyrocketed by 150.35% in 2024.
  • Zevra Therapeutics' Share-based Compensation (Yearly) stood at $2.5 million in 2020, then dropped by 2.21% to $2.4 million in 2021, then spiked by 76.27% to $4.3 million in 2022, then skyrocketed by 38.66% to $6.0 million in 2023, then soared by 150.35% to $14.9 million in 2024.